Jingyao Ma

Jingyao Ma

Auto-generated profile, based on publicly available information

Jingyao Ma

Hematology Center National Key Discipline of Pediatrics (Capital Medical University) Beijing China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
XCXiaoling Cheng
Xiaoling Cheng
LFLingLing Fu
LingLing Fu
JMJingyao Ma
Jingyao Ma
HGHao Gu
Hao Gu
ZCZhenping Chen
Zhenping Chen
RWrunhui wu
runhui wu
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with isolated thrombocytopenia and risk of hemorrhage. Treatment with eltrombopag increases and maintains hemostatic platelet counts; however, to date, long-term data are lacking on the outcome of children with ITP who are treated with eltrombopag. This prospective, observational, longitudinal cohort study evaluated the efficacy and safety of eltrombopag in pediatric patients with persistent or chronic ITP. For the 116 pediatric patients enrolled, duration of eltrombopag treatment was at least 3 months. Median effective dose was 25 mg/day, 50 mg/day, and 50 mg/day, respectively, for children age 5 years or younger, 6 to 11 years, or 12 years or older. In all, 89 patients (76.7%) achieved overall response, 53 (45.7%) achieved complete response, and 36 (31.0%) achieved response. Median platelet counts increased by week 1 and were sustained throughout the treatment period. During treatment with eltrombopag, the proportion of patients with grade 1 to 4 bleeding symptoms decreased from 83.61% at baseline to 9.88% at 6 months when only grade 1 was reported. Forty-three patients (37.1%) reported using concomitant medications at study entry, which was reduced to 1 patient (2.5%) who needed concomitant medications at 12 months. All adverse events were grade 1 or 2 according to Common Terminology Criteria for Adverse Events. No serious adverse events, cataracts, malignancies, or thromboses were reported during the study. Long-term treatment with eltrombopag was generally safe, well tolerated, and effective in maintaining platelet counts and reducing bleeding in most pediatric patients with persistent or chronic ITP. Combined with future studies, these findings will help establish how eltrombopag should best be used in the management of pediatric patients with East Asian ancestry.


5 January 2025 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
JMJingyao Ma
Jingyao Ma
YHYu Hu
Yu Hu
SDShuyue Dong
Shuyue Dong
JMJinxi Meng
Jinxi Meng
ZWZhifa Wang
Zhifa Wang
RWrunhui wu
runhui wu

22 November 2025 in American Journal of Hematology
Verified
Journal Article
Closed access
YHYu Hu
Yu Hu
HCHui Chen
Hui Chen
ZWZhifa Wang
Zhifa Wang
JMJingyao Ma
Jingyao Ma
SDShuyue Dong
Shuyue Dong
RWRunhui Wu
Runhui Wu

5 January 2025 in British Journal of Haematology
Verified
Journal Article
Closed access
NWNan Wang
Nan Wang
ZWZhifa Wang
Zhifa Wang
JLJingjing Liu
Jingjing Liu
YHYu Hu
Yu Hu
SDShuyue Dong
Shuyue Dong
RWrunhui wu
runhui wu

15 July 2025 in British Journal of Haematology
Verified
Journal Article
Closed access
JMJingyao Ma
Jingyao Ma
CCChang Cui
Chang Cui
JOJuntao Ouyang
Juntao Ouyang
ZLZheyan Lin
Zheyan Lin
XLXi Lin
Xi Lin
RWrunhui wu
runhui wu